These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20513856)

  • 41. Remission in schizophrenia: critical and systematic review.
    AlAqeel B; Margolese HC
    Harv Rev Psychiatry; 2012; 20(6):281-97. PubMed ID: 23216066
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
    Díaz I; Pelayo-Terán JM; Pérez-Iglesias R; Mata I; Tabarés-Seisdedos R; Suárez-Pinilla P; Vázquez-Barquero JL; Crespo-Facorro B
    Psychiatry Res; 2013 Apr; 206(2-3):181-7. PubMed ID: 23159063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.
    Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Huff W; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Möller HJ; Riedel M
    Schizophr Res; 2009 Sep; 113(2-3):210-7. PubMed ID: 19560901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
    Apiquian R; Fresán A; Herrera K; Ulloa RE; Lóyzaga C; de la Fuente-Sandoval C; Gutiérrez D; Nicolini H
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):403-8. PubMed ID: 14604455
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Schneider's first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis.
    Malinowski FR; Tasso BC; Ortiz BB; Higuchi CH; Noto C; Belangero SI; Bressan RA; Gadelha A; Cordeiro Q
    Braz J Psychiatry; 2020; 42(1):22-26. PubMed ID: 31166544
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Maintenance pharmacotherapy of schizophrenia: remission and the effectiveness of long-acting risperidone therapy].
    Sárosi A
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):179-87. PubMed ID: 17211053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.
    Lasser RA; Bossie CA; Gharabawi GM; Baldessarini RJ
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):427-38. PubMed ID: 15804371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
    Kinon BJ; Volavka J; Stauffer V; Edwards SE; Liu-Seifert H; Chen L; Adams DH; Lindenmayer JP; McEvoy JP; Buckley PF; Lieberman JA; Meltzer HY; Wilson DR; Citrome L
    J Clin Psychopharmacol; 2008 Aug; 28(4):392-400. PubMed ID: 18626265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder.
    Pandina G; Bilder R; Turkoz I; Alphs L
    Schizophr Res; 2013 Feb; 143(2-3):312-8. PubMed ID: 23276482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
    Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
    J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients.
    Jäger M; Riedel M; Obermeier M; Schennach-Wolff R; Seemüller F; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Bottlender R; Möller HJ
    Schizophr Res; 2010 May; 118(1-3):183-8. PubMed ID: 20181461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Risperidone in the early treatment of first-episode psychosis: a two-year follow-up study].
    Gutiérrez Fraile M; Segarra Echevarría R; González-Pinto Arrillaga A; Martínez Junquera G
    Actas Esp Psiquiatr; 2002; 30(3):142-52. PubMed ID: 12106515
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Remission in schizophrenia: analysis in a naturalistic setting.
    Eberhard J; Levander S; Lindström E
    Compr Psychiatry; 2009; 50(3):200-8. PubMed ID: 19374962
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
    Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
    Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.
    Subeesh V; Maheswari E; Singh H; Saraswathy GR; Reddy N; Chiranjeevi P
    Int J Psychiatry Clin Pract; 2020 Sep; 24(3):309-314. PubMed ID: 32338556
    [No Abstract]   [Full Text] [Related]  

  • 60. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.